Nine Diagnostics

Nine Diagnostics develops an AI-powered nanosensor diagnostic platform that enables real-time insights into disease biology using small-volume patient samples. Their core focus areas are functional precision medicine for oncology—especially gynecological cancers—and providing rapid triage tools to help clinicians distinguish between different types of cancer or non-cancerous conditions. The company has been recognized by major accelerators such as the American Cancer Society’s BrightEdge Entrepreneurs Program, Merck Digital Sciences Studio, and Novo Nordisk’s LabCentral residency program. Clinical results are not detailed publicly; the company appears to be in advanced development/pilot stages with strong industry validation but no published clinical trial outcomes yet.